The licensed indications of Ipsen Ltd's Dysport (Clostridium botulinum type A toxin-haemagglutinin complex) have been extended to include the treatment of dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, two years of age and older. Treatment is for use in hospital specialist centres. The initial recommended dose is 30 units/kg body weight given as a divided dose between both calf muscles. If only one calf muscle is affected, a dose of 15units/kg body weight should be used. The maximum dose administered must not exceed 1000 units/patient. The starting dose should be lowered if there is evidence to suggest that this dose may result in excessive weakness of the target muscles, such as for patients whose target muscles are small or patients who are to be administered multi-level injections. Clinical improvement may be expected within two weeks after injection. Injections may be repeated approximately every 16 weeks or as required to maintain response, but not more frequently than every eight weeks. See SPC for method of administration. The SPC notes that, in a study of paediatric spasticity patients, local weakness of skeletal muscle, increased incidence of falling, urinary incontinence, somnolence, asthenia, fatigue, influenza-like symptoms, and vomiting were among the side effects reported.